A bioabsorable stent is disclosed. The stent is made of a polymer and/or non-polymer material and has an elongated body having a proximate end, a distal end, and at least one open channel formed on the exterior surface of the elongated body to provide fluid communication between the proximal end and the distal end. Also disclosed is a bioabsorable stent having an elongated center rod having a proximate end and a distal end and a plurality of leaflets extending outward from the center rod and forming channels between two neighboring leaflets to provide fluid communication between the proximal end and the distal end.

A ureteral catheter for placement in a kidney, renal pelvis, and/or in a ureter adjacent to the renal pelvis of a patient, includes: an elongated tube having a proximal end, a distal end, and a sidewall extending therebetween defining at least one drainage lumen extending through the tube, wherein a proximal portion of the elongated tube is essentially free of or free of openings; and an expandable retention portion which defines a three-dimensional shape positioned to maintain fluid flow from the kidney through at least the distal end of the tube and inhibit tissue of the ureter or renal pelvis from occluding the at least one drainage lumen at the distal end of the elongated tube upon application of negative pressure through the drainage lumen, wherein the three-dimensional space defined by the expandable retention portion encloses at least a portion of the distal end of the elongated tube.

Embodiments of a Urological implant include an implant with an elongated body having a longitudinal axis. Optionally longitudinal ribs symmetrically oppose each other and are connected to elongated body. The longitudinal ribs are optionally elastically shiftable between a collapsed state and an expanded state relative to the spinal longitudinal axis, in order to retract or/and support periurethral tissue. Optionally the system includes an implant extraction handle. The extraction handle is optionally positioned proximally to the elongated body and connected to the longitudinal rib and subject to a pulling force to facilitate and/or force approximation of the longitudinal supports to the longitudinal axis. In some embodiments, an implant body includes longitudinally spaced arched members, interconnected via arch ends sequentially along a length of a first and second longitudinal rib. Optionally the arched members are elastically bendable to facilitate elastic contractibility of the implant body under a transverse compressive force.

Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.

Stents and methods for producing stents are provided. The stent includes a polymeric substrate comprised of 10-50% (w/w) of alginate and 45-85% (w/w) of gelatine and further includes a polymeric biodegradable resin for coating said polymeric substrate. The stent can also include a contrast agent. The stent can further include a crosslinking agent. The method for producing the stent includes dissolving the alginate and gelatine in water and stirring to obtain a polymeric substrate. The method also includes adding a crosslinking agent to the substrate, injecting the substrate into a mold to obtain the stent, placing the stent in a first alcohol solution, and placing the stent in a crosslinking agent solution. The method further includes placing the stent in a second alcohol solution, and a series of interchanging drying and immersing steps.

There are provided a connectable catheter system, device and methods of use thereof. The connectable catheter system, comprising: an intermediary catheter comprising an external section and a tip section, the tip section is configured to be inserted into a body of a subject; and a reconnectable indwelling stent comprising a connecting section and a target section, the target section being configured to be located within a body of the subject, wherein the connecting section of the reconnectable indwelling stent is configured to reversibly connect, within the subject body, to the tip section of the intermediary catheter to form a continuous conduit between the intermediary catheter and the reconnectable indwelling stent.

A urinary stent includes ends for deployment in the kidney and bladder, respectively, that are non-coplanar. The bladder end of the stent includes a luminary groove, covered by a sleeve of materials softer than the remainder of the stent, allowing urine at sufficient pressures to pass out from the stent, between the stent and the sleeve. The bladder end of the stent adapts its shape according to respiratory changes in the length of the stent. This shape change also prevents or reduces stent related pain.

Urologic stents that are adapted for temporary use to provide relief following treatments for benign prostatic hyperplasia and other disorders of the prostate, urethra and ureters.

A bioabsorable stent is disclosed. The stent is made of a polymer and/or non-polymer material and has an elongated body having a proximate end, a distal end, and at least one open channel formed on the exterior surface of the elongated body to provide fluid communication between the proximal end and the distal end. Also disclosed is a bioabsorable stent having an elongated center rod having a proximate end and a distal end and a plurality of leaflets extending outward from the center rod and forming channels between two neighboring leaflets to provide fluid communication between the proximal end and the distal end.

The present disclosure relates to a gastrointestinal delivery device of a chitosan dressing, where the delivery device is capable of stop bleeding, in particular in connection with TURP procedures. The delivery device may be used in all gastrointestinal bleeding applications and can be used with a biocompatible, foldable, thin profile, chitosan dressing. Various aspects of the device and its uses are provided herein.